Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control

(2013) Helena Rodbard et al.   Endocrine Practice

Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone: Interim report of a longitudinal cohort study

(2011) J. D. Lewis et al.   DIABETES CARE

Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting

(2011) C. Piccinni et al.   DIABETES CARE

Diabetes and bone health: the relationship between diabetes and osteoporosis-associated fractures

(2011) Salila Kurra et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes

(2011) K. H. Yoon et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

(2010) Debora Williams-Herman et al.   BMC Endocrine Disorders

Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18)

(2009) A. J. Scheen et al.   DIABETIC MEDICINE

Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients

(2009) Giuseppe Derosa et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Reduced postprandial proinsulinaemia and 32–33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone

(2008) Michael B. Cooper et al.   CLINICAL ENDOCRINOLOGY

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE

Rosiglitazone-Associated Fractures in Type 2 Diabetes: An analysis from A Diabetes Outcome Progression Trial (ADOPT)

(2008) S. E. Kahn et al.   DIABETES CARE